

Table S1. Reference compounds for computational screening

Compound	Use	Activity on	Evidence	Reference
Acetophenazina	Antipsychotic	SARS-CoV	In vitro-cells	[50]
Aloxistatin	Research	HCoV-OC43, HCoV-NL63, MERS-CoV, MHV-A59	In vitro-cells	[52,57]
Amodiaquine	Antimalarial	MERS-CoV, SARS-CoV	In vitro-cells	[52,57]
Anisomycin	Research	MERS-CoV, SARS-CoV	In vitro-cells	[52,57]
Arbidol	Antiviral	MERS-CoV, SARS-CoV	In vitro-cells	[52]
Astemizole	Antihistamine	SARS-CoV-2	In vitro-cells	[52,57]
Baicalin	Research	MERS-CoV, SARS-CoV	In vitro-cells	[52,57]
Baricitinib	Antirheumatic	SARS-CoV	In vitro-cells	[50]
Chlorogenic acid	Research	MERS-CoV, SARS-CoV	In vitro-cells	[52]
Chloroquine	Antimalarial	MERS-CoV, SARS-CoV	In vitro-cells	[52]
Chlorphenoxamine	Retired	SARS-CoV	In vitro-cells	[52,57]
Chlorpromazine	Antipsychotic	SARS-CoV	In vitro-cells	[52]

Cinanserin	Research	MERS-CoV, SARS-CoV	In vitro-cells	[52,57]
Clomipramine	Antidepressant	MERS-CoV, SARS-CoV	In vitro-cells	[52,57]
Cycloheximide	Research	MERS-CoV	In vitro-cells	[52,53, 57]
Cytarabine	Antineoplastic	MERS-CoV, SARS-CoV	In vitro-cells	[52,53, 57]
Darunavir	Antiviral	MERS-CoV, SARS-CoV	In vitro-cells	[52,57]
Dasatinib	Antineoplastic	SARS-CoV-2	In vitro-cells	[52,57]
Dosulepin	Antidepressant	MERS-CoV	In vitro-cells	[54]
Emetin	Research	HCoV-OC43, HCoV-NL63, MERS-CoV, MHV-A59	In vitro-cells	[52,57]
Favipiravir	Antiviral	SARS-CoV-2	In vitro-cells	[56]
Fluphenazine	Antipsychotic	HCoV-OC43, HCoV-NL63, MERS-CoV, MHV-A59	In vitro-cells	[50]
Fluspirilene	Antipsychotic	MERS-CoV, SARS-CoV	In vitro-cells	[52,57]
Gemcitabine	Antineoplastic	MERS-CoV, SARS-CoV	In vitro-cells	[52]
Glycyrrhizin	Sweetener	MERS-CoV, SARS-CoV	In vitro-cells	[52,57]

Hydroxychloroquine	Antimalarial	SARS-CoV	In vitro-cells	[50]
Hydroxyzine	Antihistamine	MERS-CoV, SARS-CoV	In vitro-cells	[52]
Imatinib	Antineoplastic	MERS-CoV	In vitro-cells	[52]
Ivermectin	Antiparasitic	SARS-CoV-2	In vitro-cells	[58]
Loperamide	Antidiarrheal	MERS-CoV, SARS-CoV	In vitro-cells	[52,57]
Lycorine	Research	MERS-CoV	In vitro-cells	[52,57]
Mefloquine	Antimalarial	MERS-CoV	In vitro-cells	[52,57]
Methotriimeprazine	Antipsychotic	MERS-CoV, SARS-CoV	In vitro-cells	[52,57]
Mofetil	Immunosuppressant	MERS-CoV	In vitro-cells	[50]
Monensin	Antibacterial (vet)	HCoV-OC43, HCoV-NL63, MERS-CoV, MHV-A59	In vitro-cells	[50]
Mycophenolic acid	Immunosuppressant	HCoV-OC43, HCoV-NL63, MERS-CoV, MHV-A60	In vitro-cells	[50]
Niclosamide	Anthelmintic	SARS-CoV	In vitro-cells	[51]
Nitazoxanide	Antiprotozoal	SARS-CoV-2	In vitro-cells	[56]
Omacetaxine	Antineoplastic	MERS-CoV, SARS-CoV	In vitro-cells	[52]

Phenazopyridine	Anesthetic	HCoV-OC43, HCoV-NL63, MERS-CoV, MHV-A60	In vitro-cells	[50]
Promethazine	Antihistamine	MERS-CoV, SARS-CoV	In vitro-cells	[52,57]
Pyrvinium	Anthelmintic	MERS-CoV	In vitro-cells	[50]
Remdesivir	Antiviral	SARS-CoV	In vitro-cells	[56]
Sotрастaurин	Research	MERS-CoV, SARS-CoV	In vitro-cells	[52,57]
Tamoxifen	Antineoplastic	MERS-CoV, SARS-CoV	In vitro-cells	[52]
Terconazole	Antifungal	MERS-CoV, SARS-CoV	In vitro-cells	[52]
Thiethylperazine	Antiemetic	MERS-CoV	In vitro-cells	[50]
Thiothixene	Antipsychotic	MERS-CoV, SARS-CoV	In vitro-cells	[52]
Toremifene	Antineoplastic	MERS-CoV	In vitro-cells	[52,53, 57]
Trifluoperazine	Antidepressant	MERS-CoV, SARS-CoV	In vitro-cells	[52,57]
Triparanol	Retired	MERS-CoV, SARS-CoV	In vitro-cells	[52]
Valinomycin	Research	SARS-CoV	In vitro-cells	[51]
Lopinavir	Antiviral	HCoV-OC43, HCoV-NL63, MERS-CoV, MHV-A59	Clinical use	[50]

Ribavirin	Antiviral	MERS-CoV	Clinical use	[50]
Saracatinib	Research	MERS-CoV	Clinical use	[50]
6-Mercaptopurine	Antineoplastic	MERS-CoV	In vitro-free cells	[50]
6-Thioguanine	Antineoplastic	MERS-CoV	In vitro-free cells	[50]
Disulfiram	Prevent alcohol dependency	MERS-CoV	In vitro-free cells	[50]
N-ethylmaleimide	Research	MERS-CoV	In vitro-free cells	[50]
Nutlin-3A	Research	MERS-CoV	In vitro-free cells	[50]
Benztropine	Anticholinergic	SARS-CoV-2	Computational proposal	[55]

Table S2. Reference compounds with proven activity against Mpro and PLpro of SARS-CoV-2

Compound	IC ₅₀ against SARS-CoV-2 Mpro (μM)	IC ₅₀ against SARS-CoV-2 PLpro (μM)	Reference
Amodiaquine	No reported	19.85	[67]
Baicalin	6.41	177.6	[64, 69]
Baricitinib	25.31	No reported	[63]
Chlorogenic acid	29.48	0.54	[66]
Cinanserin	124.93	No reported	[62]
Glycyrrhizin	< 30	No reported	[61]
Ivermectin	21.53	No reported	[60]
Loperamide	No reported	33.5	[65]
Niclosamide	18.7	16.6	[59]
Tamoxifen	No reported	41.0	[59]
6-Mercaptopurine	No reported	21.6	[68]
6-Thioguanine	No reported	5.0	[68]
Disulfiram	2.1	No reported	[70]

Table S3. Compounds evaluated experimentally.

Internal ID	ZINC15 ID	SMILES	Supplier	Cat. number
1	ZINC66987	CN(C)C1=CC=C(C=C1)C2NC3=CC=CC4=C3C(=CC=C4)N2	Vitas M Chemical	STK005051
2	ZINC299345	C1=CC=C(C=C1)OC(=O)C2=CC=CC=C2OC(=O)C3=CC=CO3	Vitas M Chemical	STK388138
3	ZINC600324	COCl=C2=C(C=C1)SCCN(C2)C(=O)CCN3CCC(CC3)CC4=CC=CC=C4	Sigma-Aldrich	SML0549
4	ZINC3313600	CN1CCCN(CC1)S(=O)(=O)C2=CC3=CC=CC=C3C=C2	Enamine	Z45547537
5	ZINC3861553	CN(C)C1=CC=C(C=C1)C(C2=CC=C(C=C2)N(C)C)C3=CC=C(C=C3)N(C)C	TargetMol	T1343
6	ZINC4272012	CN(C)C1=CC=C(C=C1)C(C2=CC=CC=C2)C3=CC=C(C=C3)N(C)C	MedChemExpress	HY-D0300
7	ZINC4759224	CN(C)C1=CC=C(C=C1)C(=O)N(CC2=CC=CC=C2)CC3=CC=CC=C3	Chembridge	P-7363096
10	ZINC8579480	CCN(CC1=CC2=CC=CC=C2NC1=O)C(=O)C3=CN=CC=C3	Vitas M Chemical	STL038212
11	ZINC9435742	CC1=CC2=C(C(=CC(=O)O2)C)C(=C1)OCC(=O)N3CCC(CC3)(C4=CC=C(C=C4)Cl)O	Vitas M Chemical	STK608237
13	ZINC13878776	CC1=CC(=C(C(=O)N1)[N+](=O)[O-])OC(=O)C2=CC3=CC=CC=C3C=C2	Life Chemicals Inc.	F1826-0081
13a	ZINC4248385	CC1=CC(=C(C(=O)N1)[N+](=O)[O-])OC(=O)C2=CC3=CC=CC=C32	Life Chemicals Inc.	F1826-0080
13b	ZINC13523222	CC1=CC=C(C=C1)C(=O)OC2=C(C(=O)NC(=C2)C)[N+](=O)[O-]	Life Chemicals Inc.	F1826-0032
13c	ZINC4248365	CC1=CC(=C(C(=O)N1)[N+](=O)[O-])OC(=O)C2=CC=C(C=C2)Br	Life Chemicals Inc.	F1826-0059
14	ZINC19360158	COCl=C2=C(C=C1)CN2CCN(CC2)CC3=CC4=CC=CC=C4C=C3	Vitas M Chemical	STK145318
18	ZINC19782432	CC(C)CC(=O)N1CCN(CC1)CC2=CC3=CC=CC=C3C=C2	Asinex	P-596350389

Table S4. Molecular docking scores of compounds 13–13c

Compound	Score (kcal/mol)
13	-6.83
13a	-6.81
13b	-6.41
13c	-6.67




Figure S1. Concentration–response curve for the reported Mpro inhibitor GC376 in our FRET assay. A representative assay form two performed is shown.




Figure S2. Binding mode of identified Mpro inhibitors predicted by molecular docking for the compound **13** (a), **13a** (b), **13b** (c), and **13c** (c). Nomenclature for two-dimensional interaction diagrams (e).




Figure S3. Molecular dynamics simulation of SARS-CoV-2 Mpro/13c complex. (a) Root Mean Square Deviation (RMSD) of ligand **13c** (green line) and Mpro (gray line). Mpro RMSD was 2.32 ± 0.31 Å. (b) Root Mean Square Fluctuation (RMSF) of Mpro alpha-carbons. Values for residues 43 to 54, corresponding to a loop with high fluctuation, are highlighted in red. (c) Comparison of enzyme-ligand complex at initial conformation (Mpro: white cartoon, 43-54 loop: blue, ligand: transparent green) and after 45 ns of simulation (Mpro: pale cyan cartoon, 43-54 loop: red, ligand: solid green). Arrows indicate temporal evolution.




Figure S4. Cytotoxicity of SARS-CoV-2 Mpro inhibitors on CCL81 Vero cells exposed for 72 h to the selected compounds. Concentration-response curves for GC376 (0.078–10 μ M), 13-13b (0.78–100 μ M) and 13c (0.39–50 μ M). Data were normalized against the corresponding vehicle control (\blacktriangle). Vehicle was DMSO 0.2% for GC376, 13, 13a, 13b, and DMSO 0.5% for 13c. Plots show the mean \pm the standard error of the mean (SEM) from three independent experiments. All experiments included cells without treatment (\triangle), and the cytotoxic drug doxorubicin 2.5 μ M (\blacksquare) as positive control.




Figure S5. Cytopathic effect elicited by SARS-CoV-2 on cell cultures treated with Mpro inhibitors. **(a)** Representative Vero CCL8 cultures showing the cytopathic effect elicited by SARS-CoV-2 (72 h) in presence of compounds **13–13c** or the positive control GC376. The arrangement of the plate is shown at the top: Dil: dilution. **(b)** Representative Vero CCL8 cultures employed as controls. These control plates were run simultaneously than those shown in A.